Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07310420 · ClinicalTrials.gov registry record · Phase 1
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer
A Phase 1 study, sponsored by TerSera Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT07310420 is a Phase 1 study that is actively recruiting participants, run by TerSera Therapeutics. The registered enrollment target is 88 participants.
The verdict
NCT07310420, a Phase 1 study, is actively recruiting participants, sponsored by TerSera Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
The primary objective of this trial is to evaluate ovarian suppression following treatment with ZOLADEX 10.8 mg by luteinizing hormone (LH).
Interventions
- DRUG ZOLADEX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2026-06-30 |
| Est. Completion | 2027-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07310420
The ClinicalTrials.gov registry entry for NCT07310420 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TerSera Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ZOLADEX is the first listed.
NCT07310420 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07310420 about?
NCT07310420 is a clinical study titled "A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer". The primary objective of this trial is to evaluate ovarian suppression following treatment with ZOLADEX 10.8 mg by luteinizing hormone (LH).
What is the current status of trial NCT07310420?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2026-06-30. Estimated completion is 2027-03-30.
What interventions are being tested in trial NCT07310420?
The interventions under investigation include: ZOLADEX (DRUG).
Who is sponsoring clinical trial NCT07310420?
This trial is sponsored by TerSera Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.